Anti-PD-1 ICI and BRAF-/MEK-inhibition with the dabrafenib plus trametinib (restricted to patients with BRAFV600-mutant melanoma) have become standard adjuvant treatment options that significantly improve RFS in patients with resectable stage III/IV disease. The gene discussed is MAP2K7; the disease is melanoma.